BIOEQUIVALENCE OF FIXED-DOSE COMBINATIONS OF DAPAGLIFLOZIN/METFORMIN RELATIVE TO SINGLE COMPONENTS IN HEALTHY SUBJECTS

被引：0
|
作者：
Boulton, D. W. [1 ]
Chang, M. [1 ]
Griffen, S. C. [2 ]
Kitaura, C. [1 ]
Lubin, S. [1 ]
Pollack, A. [1 ]
LaCreta, F. [1 ]
机构：
[1] Bristol Myers Squibb Co, Princeton, NJ USA
[2] JDRF, New York, NY USA
来源：
CLINICAL THERAPEUTICS | 2015年 / 37卷 / 08期
关键词：
D O I：
10.1016/j.clinthera.2015.05.283
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：E98 / E99
页数：2
相关论文
共 50 条
  • [11] Bioequivalence of Saxagliptin/Metformin Immediate Release (IR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin IR Tablets in Healthy Adult Subjects
    Vijay V. Upreti
    Chi-Fung Keung
    David W. Boulton
    Ming Chang
    Li Li
    Angela Tang
    Bonnie C. Hsiang
    Donette Quamina-Edghill
    Ernst U. Frevert
    Frank P. LaCreta
    Clinical Drug Investigation, 2013, 33 : 365 - 374
  • [12] Bioequivalence of Saxagliptin/Metformin Immediate Release (IR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin IR Tablets in Healthy Adult Subjects
    Upreti, Vijay V.
    Keung, Chi-Fung
    Boulton, David W.
    Chang, Ming
    Li, Li
    Tang, Angela
    Hsiang, Bonnie C.
    Quamina-Edghill, Donette
    Frevert, Ernst U.
    LaCreta, Frank P.
    CLINICAL DRUG INVESTIGATION, 2013, 33 (05) : 365 - 374
  • [13] Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects
    Grill, Simon
    Bruderer, Shirin
    Sidharta, Patricia N.
    Antonova, Mariya
    Globig, Susanne
    Carlson, James
    Schultz, Armin
    Csonka, Denes
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (12) : 2424 - 2434
  • [14] Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Subjects
    Boulton, David W.
    Smith, Charles H.
    Li, L.
    Huang, Jian
    Tang, Angela
    LaCreta, Frank P.
    CLINICAL DRUG INVESTIGATION, 2011, 31 (09) : 619 - 630
  • [15] Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Subjects
    David W. Boulton
    Charles H. Smith
    L. Li
    Jian Huang
    Angela Tang
    Frank P. LaCreta
    Clinical Drug Investigation, 2011, 31 : 619 - 630
  • [16] Fed and fasted bioequivalence assessment of two formulations of extended-release fixed-dose combination dapagliflozin/metformin (10/1,000 mg) tablets in healthy subjects
    Lee, Hae Won
    Kang, Woo Youl
    Park, Ji Seo
    Lee, Jae Hwa
    Gwon, Mi-Ri
    Yang, Dong Heon
    Kim, Eun Hee
    Park, Soo-Jin
    Yoon, Young-Ran
    Seong, Sook Jin
    TRANSLATIONAL AND CLINICAL PHARMACOLOGY, 2023, 31 (02) : 105 - 113
  • [17] The proliferation of irrational metformin fixed-dose combinations in India
    Evans, Valerie
    Pollock, Allyson M.
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (02): : 98 - 100
  • [18] Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects
    Kang, Woo Youl
    Seong, Sook Jin
    Ohk, Boram
    Gwon, Mi-Ri
    Kim, Bo Kyung
    Na, Sookie
    Kim, Hyun-Ju
    Yoon, Young-Ran
    Lee, Hae Won
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2018, 56 (01) : 43 - 52
  • [19] Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
    Dawra, Vikas Kumar
    Liang, Yali
    Wei, Hua
    Pelletier, Kathleen
    Shi, Haihong
    Hickman, Anne
    Bass, Almasa
    Terra, Steven G.
    Zhou, Susan
    Krishna, Rajesh
    Sahasrabudhe, Vaishali
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (01): : 50 - 61
  • [20] Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Chinese Subjects
    Anders Gummesson
    Haiyan Li
    Michael Gillen
    John Xu
    Mohammad Niazi
    Boaz Hirshberg
    Clinical Drug Investigation, 2014, 34 : 763 - 772
12345